MEDIC develops a cancer drug target discovery platform that integrates CRISPR functional genomics with patient tumor-like cancer models. This platform identifies potential targets for cancer drug development, aiming to accelerate the discovery of new cancer treatments.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer drug development often misses potential biomarkers and novel drug targets, hindering the ability to stratify patients and develop effective, personalized treatments. Traditional methods lack the accuracy and translatability needed to pinpoint key genetic features with real translational impact.
Solution
MEDiC offers a cancer drug target discovery platform that integrates CRISPR functional genomics with patient tumor-like cancer models to address the limitations of current drug development approaches. The platform utilizes a proprietary tumor-immune co-culture system, enabling the systematic assessment of cancer mutations for tumor growth, immune response, and drug response. By generating and cultivating millions of CRISPR tumor variants in the presence of human T cells, MEDiC's platform identifies tumor-intrinsic and immuno-oncological drug targets. This approach facilitates the discovery of biomarkers, resistance mutations, and genes associated with synthetic lethality, accelerating the development of novel cancer treatments.
Target Audience
MEDiC's primary customers are pharmaceutical companies and research institutions focused on developing first-in-class oncology drugs and identifying novel biomarkers for existing therapeutics.
Features
- CRISPR-based functional genomics platform for systematic target discovery
- 3D tumor models to mimic the tumor microenvironment
- Proprietary tumor-immune co-culture system for assessing drug and immune response
- High-throughput screening of CRISPR tumor variants
- Identification of biomarkers, synthetic lethality, and resistant mutations
- NGS analysis to identify key genetic features